China CDC weekly · 2024
Immunogenicity of Short-Course, High-Dose Hepatitis B Vaccination in Patients with Chronic Kidney Disease - Shanxi Province, China, 2019-2020.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gao Linying, Cui Xufeng, Mo Xinyuan, Men Zhaoyue, Xu Xiuyang, Yao Tian, Wang Jianmin, Liu Hongting, Guo Hongping, Chai Guowei, Liu Liming, Wang Fuzhen, Liang Xiaofeng, Wang Suping, Feng Yongliang
Аннотация
WHAT IS ALREADY KNOWN ABOUT THIS TOPIC?: As one of the populations at high risk of hepatitis B virus (HBV) infection, patients with chronic kidney disease (CKD) require rapid and effective development of hepatitis B surface antibodies (anti-HBs).
WHAT IS ADDED BY THIS REPORT?: The short-course, high-dose regimen of hepatitis B vaccination rapidly induced comparable immunological responses to the routine regimen, achieving a seroconversion rate of 88.5%, a high-response rate of 64.1%, and anti-HBs geometric mean concentrations of 824.1 mIU/mL.
WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE?: The short-course, high-dose regimen represents an effective rapid immunization strategy for CKD patients, particularly when administered prior to immunosuppressive therapy. This study provides compelling evidence for optimizing immunization protocols in the CKD population.
WHAT IS ADDED BY THIS REPORT?: The short-course, high-dose regimen of hepatitis B vaccination rapidly induced comparable immunological responses to the routine regimen, achieving a seroconversion rate of 88.5%, a high-response rate of 64.1%, and anti-HBs geometric mean concentrations of 824.1 mIU/mL.
WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE?: The short-course, high-dose regimen represents an effective rapid immunization strategy for CKD patients, particularly when administered prior to immunosuppressive therapy. This study provides compelling evidence for optimizing immunization protocols in the CKD population.